Obstetric Liposomal Bupi[INVESTIGATOR_889234]: a Single-blind Pi[INVESTIGATOR_6261]
[STUDY_ID_REMOVED]
PI: [INVESTIGATOR_889235], MD, MSCI
Version Date 9/11/2022
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page [ADDRESS_1245000] Cesarean Pain Control:  
a single -blind pi[INVESTIGATOR_889236]  
(ObLiBupi [INVESTIGATOR_529212])  
 
Protocol Number: UnityPoint Health- Meriter IRB#: 2021 -005 
Principal Investigator: [INVESTIGATOR_74597] M. Antony , MD, MSCI  
 
 
 
This document is confidential. 
No part of it may be transmitted, reproduced, published, or used by [CONTACT_678073]. 
 
 
 
  
 
Protocol Version History  
Protocol Version  Version Date  Brief description of protocol modification/actions requested, if any  
Version 1.7 06/20/2021  ***Do not update version # until final draft***  
   
   
   
   
   
   
 
 
  
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page [ADDRESS_1245001] Selection  ..............................................................................................................................................................  16 
8.1 Target Study Sample Size  ...........................................................................................................................................  16 
8.2 Inclusion Criteria  .......................................................................................................................................................... 16 
8.3 Exclusion Criteria .........................................................................................................................................................  17 
8.4 Recruitment  ................................................................................................................................................................ . 18 
8.5 Retention Strategies  ....................................................................................................................................................  18 
8.6 Early Termination and Withdrawal  ..............................................................................................................................  18 
9. Study Intervention  .............................................................................................................................................................  18 
9.1 Study Intervention Description  ..............................................................................................................................  18 
9.2 Source  .........................................................................................................................................................................  19 
9.3 Packaging and Labeling ..............................................................................................................................................  19 
9.4 Preparation  .................................................................................................................................................................. 20 
9.5 Storage and Stability  ................................................................................................................................................... 20 
9.6 Accountability  ..............................................................................................................................................................  20 
9.8 Randomization and Blinding  ........................................................................................................................................ 23 
9.9 Study Intervention Compliance  ...................................................................................................................................  24 
9.10 Concomitant Therapy  ................................................................................................................................................  25 
9.11 FDA IND Compliance ................................................................................................................................................  25 
10. Study Visits and Procedures  ...........................................................................................................................................  26 
10.1 Study Calendar  .......................................................................................................................................................... 26 
10.2 Screening and Enrollment  .........................................................................................................................................  26 
10.3 On -Study/Follow -up Activities  ...................................................................................................................................  31 
10.4 Unscheduled Visits  ....................................................................................................................................................  32 
10.5 Early Termination and Withdrawal  ............................................................................................................................ 32 
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page [ADDRESS_1245002] Retention  .......................................................................................................................................................  33 
11.3 Handling of Data to Ensure Confidentiality ................................................................................................................  33 
11.4 Data collection forms  ................................................................................................................................................. 34 
11.5 Data Confidentiality  ................................................................................................................................................... 34 
11.6 Records Retention  .....................................................................................................................................................  34 
12. Assessment of Safety  .....................................................................................................................................................  35 
12.1 Risk/Benefit Assessment  ...........................................................................................................................................  35 
12.2 Unanticipated Findings  ..............................................................................................................................................  35 
12.5 Adverse Event (AE) Definition  ...................................................................................................................................  36 
12.6 Serious Adverse Event (SAE) Definition  ................................................................................................................... 36 
12.7 Documenting and Reporting of AEs, SAEs & Ups  .................................................................................................... 37 
12.8 Stoppi[INVESTIGATOR_1869]  .......................................................................................................................................................... 38 
13. Study Analysis  ................................................................................................................................................................ . 38 
13.1 Statistical Hypothesis  ................................................................................................................................................  38 
13.2 Sample Size Justification ...........................................................................................................................................  39 
13.3 Statistical Methods  ....................................................................................................................................................  39 
13.4 Planned Interim Analysis  ...........................................................................................................................................  39 
14. Regulatory, Ethical, and Study Oversight Considerations  ..............................................................................................  40 
14.1 Safety Oversight  ........................................................................................................................................................ 40 
14.2 Protocol Deviations  ....................................................................................................................................................  40 
14.3 Publication Plan  .........................................................................................................................................................  40 
References  ............................................................................................................................................................................  41 
 
 
  
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page [ADDRESS_1245003] of this study are informed about their obligations in meeting the above commitment.  
 
 
 
 
PRINTED OR TYPED NAME    
 
[CONTACT_889416]      
 
  
[INVESTIGATOR_889237] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page [ADDRESS_1245004] Research Organization  
CTCAE  Common Terminology Criteria for Adverse Events  
DCC  Data Coordinating Center  
DHHS  Department of Health and Human Services  
DSMB  Data & Safety Monitoring Board  
DSMC  Data and Safety Monitoring Committee  
DSMP  Data & Safety Monitoring Plan  
DMC  Data Monitoring Committee  
EDC  Electronic Data Capture  
HER  Electronic Health Record  
FDA Food and Drug Administration  
GCP  Good Clinical Practice  
HIPAA  Health Insurance Portability and Accountability Act  
IB Investigator’s Brochure  
ICH E6  International Council on Harmonisation Guidance for Industry, Good Clinical Practice: Consolidated 
Guidance  
ICTR  Institute for Clinical and Translational Research  
IRB Institutional Review Board  
MOP  Manual of Procedures  
OHRP  Office for Human Research Protections  
Ob/Gyn  Department of Obstetrics and Gynecology  
PHI Protected  Health Information  
PI [INVESTIGATOR_889238] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page [ADDRESS_1245005] Cesarean Pain Control: Single Blind RCT  
Protocol Number  UnityPoint Health -Meriter IRB#: *** 
ClinicalTrials.gov 
Identifier  ClinicalTrials.gov Identifier: ***  
Number of  Site(s)  Single center  
Main Inclusion 
Criteria o Singleton or multifetal pregnancy  
o Able to receive neuraxial analgesia  
o Planned/ scheduled Cesarean delivery OR non- urgent Cesarean 
delivery with adequate time to consider and consent to the study  
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page 7 of 42 Main Exclusion 
Criteria o Known hypersensitivity to bupi[INVESTIGATOR_10319]  (defined as a history of a reaction or 
allergy to bupi[INVESTIGATOR_10319] (injectable, intravenous, or transdermal) reported by 
[CONTACT_889375] 
o Contraindication to regional analgesia  
o Positive urine drug screen at admission to the hospi[INVESTIGATOR_307], if ordered for clinical 
purposes.  
o Current opi[INVESTIGATOR_889239] 
o Chronic opi[INVESTIGATOR_889240], either patient reported or documented 
in the medical record, defined as opi[INVESTIGATOR_889241] >3 months  
o Planned cesarean hysterectomy (excluded due to anticipated blood loss and alternative pain control measures, possible prolonged intubation)  
o Planned vertical midline incision (excluded due to possible different postpartum 
pain) 
o Presence of renal dysfunction precluding the use of NSAIDs (NSAIDs are part of the usual postpartum pain regimen/ hospi[INVESTIGATOR_23155]) per discretion of the treating physician or PI  
o Ischemic heart disease, congestive heart failure, or cardiomyopathy of pregnancy  precluding the use of NSAIDs (NSAIDs are part of the usual 
postpartum pain regimen/ hospi[INVESTIGATOR_23155]) per discretion of the treating physician or PI 
o Significant liver dysfunction precluding the use of acetaminophen (acetaminophen is part of the usual postpartum pain regimen/ hospi[INVESTIGATOR_23155]) per discretion of the treating physician or PI 
o Coagulopathy  
o Planned discharge from the hospi[INVESTIGATOR_889242] [ADDRESS_1245006]-operative scheduled NSAIDs for any reason, such as 
allergy to ketorolac or ibuprofen, or renal dysfunction precluding NSAID use 
o Seizure disorder : Specifically, poorly controlled seizure disorder defined as 
having had a seizure within the last three years despi[INVESTIGATOR_889243]-compliance.  
o Cardiac disease or arrhythmia: Defined as ischemic heart disease, 
peripartum cardiomyopathy, heart failure (with reduced or preserved ejection 
fraction, compensated or decompensated). Patients with a remote history of non-cyanotic pediatric cardiac surgery (like a VSD closure or PDA ligation as a child) do not need to be excluded. History of adult cardiac surgery without ongoing problems or treatments other than chronic anticoagulation (mitral valve repair for MVP or aortic valve replacement for bicuspid aortic valve for 
example) would not need to be excluded. History of repaired congenital 
cyanotic heart disease should be considered for exclusion, ultimately up to the anesthesiologist that day. A patient with a history of arrhythmias not requiring medication or ablation would NOT need to be excluded and could be included in the study. History of ablation or active anti -arrhythmic medication should be 
considered for exclusion.  
o Hypoxia:  Defined as requiring supplemental oxygen during the day.  
o Acidosis. This will be uncommon in our population, but if someone has active 
diabetic ketoacidosis will exclude.   
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page [ADDRESS_1245007] via surgical approach (abdominal approach).  
The intervention arm will receive [ADDRESS_1245008] via surgical approach (abdominal approach).  
Total Number of 
Subjects  60 Subjects  
Study Population Pregn ant women undergoing scheduled cesarean delivery  
Statistical Methodology  The primary outcome of total opi[INVESTIGATOR_40533] (in OME) will be compared  via Student’s t -
test or Mann-Whitney U test if the distribution is non-normally distributed , and 
additional outcomes will be assessed via Student’s t-test, Chi -squared, or non -
parametric tests, as appropriate. Statistics will be performed by [CONTACT_889376].  
Estimated 
Enrollment Period [ADDRESS_1245009] enrollment  
 
 
  
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page [ADDRESS_1245010] of all key personnel and roles: 
 
Principal Investigator
  [INVESTIGATOR_74597] M. Antony, MD, MSCI  
Department of Obstetrics & Gynecology  
Division of Maternal -Fetal Medicine  
University of Wisconsin School of Medicine and Public Health 
[ADDRESS_1245011], 4th Floor, MFM  
Madison, WI [ZIP_CODE] 
[EMAIL_16940]  
Tel: 608-417 -6099 
Fax: 608-417 -4270 
UnityPoint Health-Meriter Hospi[INVESTIGATOR_307], Madison, WI 
 
Participating Site (s) UnityPoint Health, Meriter Hospi[INVESTIGATOR_307]  
[ADDRESS_1245012], Madison, WI [ZIP_CODE]  
Co-Investigator(s)  Luther Gaston, MD  
Division of Academic Specialists in General Obstetrics and Gynecology  
[ADDRESS_1245013] Kathleen M. Antony, MD, MSCI  (above)  
[EMAIL_16940]  
 
Lisa Grady  
[EMAIL_16941]  
Biostatistician  Scott Hetzel , MS 
Biostatistics and Medical Informatics  
207G WARF  
[EMAIL_16942]  
[PHONE_18395]  
 
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page [ADDRESS_1245014] common major surgical procedure performed in the [LOCATION_002], with rate of 
about 31.9% of deliveries.(1) Pain management following cesarean birth involves a combination of opi[INVESTIGATOR_285774]-opi[INVESTIGATOR_83269]. Prescription opi[INVESTIGATOR_889244], with a four -fold increased rate of unintentional overdose using prescription opi[INVESTIGATOR_713273] 2000-2010.(2) 
 
An evaluation by [CONTACT_889377][INVESTIGATOR_889245], including after 
cesarean delivery .(3,4) Between 1 in every 50 
and 1 in every 300 women undergoing cesarean delivery become chronic opi[INVESTIGATOR_45155].(4,5) If this rate holds true for women 
delivering at UnityPoint Health-Meriter, between 4 and 27 women delivering at Meriter would potentially become chronic opi[INVESTIGATOR_889246]. Women delivering at UnityPoint Health-Meriter also use more opi[INVESTIGATOR_889247]. During 
2016-2017, the per -woman average 
cumulative oral morphine milligram equivalent (MME) dose in the first 24 hours postpartum 
for opi[INVESTIGATOR_2480]-naive women undergoing cesarean 
delivery  was 104.4 mg. Based upon this high 
cumulative opi[INVESTIGATOR_40533], a standardized 
analgesia regimen was created in 2018 which prioritized scheduled acetaminophen and nonsteroidal anti -inflammatory drugs 
(NSAIDs). After this protocol was implemented, the per -woman  average 
cumulative MME dose was reduced to 82.[ADDRESS_1245015] 24 hours postpartum exceeds the opi[INVESTIGATOR_889248] a range of MMEs in the literature of 2.5-35 mg.(6– 9)  
 Efforts to reduce opi[INVESTIGATOR_889249]. There is a nationwide 
opi[INVESTIGATOR_8562], and the Madison community is no exception; any intervention to decrease future opi[INVESTIGATOR_889250]. For the purpose of this protocol, the term “opi[INVESTIGATOR_2438]” refers to both natural opi[INVESTIGATOR_889251], such as fentanyl. The rate of respi[INVESTIGATOR_889252],(10)  so efforts to decrease the total dose may decrease 
the frequency of such events.  
 [ADDRESS_1245016]-
cesarean
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page [ADDRESS_1245017] formed such a group at Meriter aimed at enhancing recovery after cesarean surgery (ERACS) and we are developi[INVESTIGATOR_889253].    
However, the experience of other institutions has shown that, while these efforts reduce cumulative MME dose, even with these ERACS 
protocols in place that there is additional benefit to the use of liposomal bupi[INVESTIGATOR_889254] (TAP) block. The rationale for additional benefit of 
bupi[INVESTIGATOR_889255] (one portion of the ERACS protocol) has effect up to 12-[ADDRESS_1245018] between the internal oblique muscle and transversus abdominis muscle in the 
area of the iliohypogastric and ilioinguinal nerves (Figure).  
 
 Liposomal bupi[INVESTIGATOR_14072] a long-acting local anesthetic which is FDA approved for single dose infiltration into a surgical site or for nerve blocks. With liposomal bupi[INVESTIGATOR_10319], the active drug (bupi[INVESTIGATOR_10319]) is encapsulated in a liposomal platform and released slowly over the course of days with an approximate 72 hour duration.(11)   
One prior retrospective study conducted in a center with a fully implemented obstetrical enhanced recovery after surgery protocol already in place found that when they added liposomal bupi[INVESTIGATOR_889256] (TAP) block, they found a 47% reduction in total post-cesarean opi[INVESTIGATOR_17023], a 46% reduction in pain scores, and a decreased length of hospi[INVESTIGATOR_889257] 4.3 days to 3.1 
days  (P <0.001).(12) As noted, this center already had implemented intrathecal morphine, scheduled 
acetaminophen and NSAIDs, and other components that we are aspi[INVESTIGATOR_889258]. Thus, the benefit they demonstrated to the liposomal bupi[INVESTIGATOR_889259]. More recently, a 
randomized controlled trial utilizing liposomal bupi[INVESTIGATOR_889260] (in both the intervention and control arm) found a 51.6% reduction in opi[INVESTIGATOR_14048] 72 hours after cesarean (P=0.0002) and also found that 54% of women in the intervention arm used 
less than 15 mg of MME total  compared to 24.7% in the control arm (P =0.0012) .(9) 
 TAP plane blocks via the usual anesthesia-administered technique, however, require placement by [CONTACT_634829].(13)  The anesthesiologist needs specialized training, and ultrasound guidance is required to 
ensure proper placement.(13)  Placement by [CONTACT_889378].(12,14– 16) Placement of this block 
is also more challenging in the setting of obesity, (17) and 60% of the patients undergoing cesarean birth at 
UnityPoint Health-Meriter have obesity.   Therefore, a surgical, or abdominal, approach to the transversus abdominus plane block has been proposed.  
In 2011 Owen et al. pi[INVESTIGATOR_889261] 16 women undergoing cesarean delivery.(15)  They used 0.5% 
bupi[INVESTIGATOR_889262] [ADDRESS_1245019] for opi[INVESTIGATOR_37007].(15)  Thus, the surgical 
approach to TAP block was effective. An RCT then compared surgeon-administered TAP block compared to anesthesiologist-placed TAP block and found no significant differences in opi[INVESTIGATOR_889263], therefore, the mode of administration does not appear to impact the efficacy  of the block .(14) The RCT 

The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page [ADDRESS_1245020]-administered TAP block also found the time 
was significantly less for the surgeon -administered TAP block (2.4 minutes versus 12.1 minute, P <0.001) and 
the time spent in the operating room was also significantly lower (55.3 versus 77.9 minutes, P <0.001).(14) 
Finally, the patient satisfaction with pain scores was not different (satisfaction 7.8 with surgical TAP versus 6.7 
with conventional TAP, P 0.11).(14)  Finally, a study that sought to assess the feasibility of surgical TAP block 
on a larger scale found that the procedure was safe, easy, and effective and did not require any specialized equipment.(16)  So placement of the TAP block via a surgical or abdominal approach by [CONTACT_889379] -surgeon 
is feasible, equally effective, and faster than placement by [CONTACT_108424]. However, the studies 
demonstrating the effectiveness of this approach used bupi[INVESTIGATOR_174053], both of which have a 
relatively short duration of action. Additionally, none of these three studies utilized intrathecal (neuraxial) morphine.(14– 16)  
 Intrathecal, or neuraxial,  morphine is a long acting spi[INVESTIGATOR_889264] 24 hours after spi[INVESTIGATOR_889265].(18)  The effect of neuraxial morphine would be expected to exceed the effect of regular bupi[INVESTIGATOR_889266] 7 hours.(19)  Therefore, only liposomal bupi[INVESTIGATOR_889267].   There is a strong interest in reducing post-cesarean opi[INVESTIGATOR_889268]. Collaborators in the 
department of anesthesia, nurses, and the pharmacy are all committed to reducing opi[INVESTIGATOR_8556], 
particularly given the risk of post-operative respi[INVESTIGATOR_889269]. The rate of moderate to severe respi[INVESTIGATOR_889270] 184/10,000 deliveries compared to 1.6/10,000 in the general obstetrical population. This is 112-fold higher than reported in the l iterature.(20) I n our population we 
found the risk of respi[INVESTIGATOR_889271].(20)  If successful, 
this project will decrease post-operative opi[INVESTIGATOR_889272]-operative respi[INVESTIGATOR_889273]. Future efforts will focus on continuing to reduce 
opi[INVESTIGATOR_889274]-cesarean population.  
 This study will be conducted in compliance with this protocol, good clinical practice, and under the supervision of the Meriter Institutional Review Board (IRB). The population studied will include pregnant women who are 
at least 18 years old who are pregnant who will be delivered via cesarean delivery  at UnityPoint Health-Meriter 
Hospi[INVESTIGATOR_307]. This study will also not start until the multidisciplinary obstetrical enhanced recovery after cesarean 
surgery (ERACS) protocol is completed and fully operational and implemented to reduce confounding by [CONTACT_889380]-protocol implementation on patient pain and opi[INVESTIGATOR_2441].  
 
5.[ADDRESS_1245021]- Cesarean pain and are acutely at risk of moderate to severe respi[INVESTIGATOR_62616]. (3,4) T he rate of respi[INVESTIGATOR_889252], efforts to decrease the 
opi[INVESTIGATOR_889275]. (10)  Reducing the opi[INVESTIGATOR_889276]. There are many ongoing completed and ongoing studies nationwide seeking to reduce post-
cesarean opi[INVESTIGATOR_2441], some of which could be integrated into practice once completed.(8)  
 This study seeks to identify whether the addition of liposomal bupi[INVESTIGATOR_889277] 48 hours after 
cesarean. The liposomal bupi[INVESTIGATOR_889278] (bupi[INVESTIGATOR_889279])  will both also receive the 
current standard of care, which at UnityPoint Health-Meriter consists of scheduled NSAIDs, acetaminophen, 
and “rescue” opi[INVESTIGATOR_2438]. This study will also be started after the enhanced recovery after cesarean (ERAC) 
protocol has started and therefore all women will have received intrathecal or neuraxial morphine.   
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page 13 of 42 This study is novel in its surgical approach to the TAP block which has not previously been performed in 
women receiving intrathecal morphine and also is novel in that it will be using liposomal bupi[INVESTIGATOR_10319]. The 
average BMI of our cesarean delivery population is also higher than reported in the existing investigations 
utilizing surgical TAP block, thus while we are not specifically targeting women with obesity, our study will likely include a significant proportion of women with obesity. (14–16) 
 If successful, this pi[INVESTIGATOR_889280] a larger randomized controlled trial. The effect size found via this pi[INVESTIGATOR_889281]. If that second trial successfully demonstrates that surgical TAP block with liposomal 
bupi[INVESTIGATOR_889282]- cesarean opi[INVESTIGATOR_2441], pain, and length of stay compared to women 
receiving regular bupi[INVESTIGATOR_10319], then a cost-benefit analysis will be performed and it may  be considered for 
more routine use at UnityPoint Health-Meriter and possibly elsewhere.  
 
Bupi[INVESTIGATOR_889283]. However, it does have risks. Bupi[INVESTIGATOR_889284].(11)  Giving higher 
doses of bupi[INVESTIGATOR_31974] (regular bupi[INVESTIGATOR_10319]) in hopes of prolonging anesthesia can be harmful.(11)  In 
contrast, liposomal bupi[INVESTIGATOR_889285], thus allows for a longer duration of effect without increasing plasma concentrations.(11)  
Several publications utilizing regular bupi[INVESTIGATOR_889286], for incision infiltrations, and for TAP blocks. These studies have demonstrated its safety when used in the operating room 
and with lasting effect into the immediate postpartum period.(13,16,21– 26) Its safety has also been 
demonstrated with lactation.(27)  Liposomal bupi[INVESTIGATOR_889287].(9,12,28,29)   
 
For the purpose of this study, the control arm and intervention arm will receive the following medications via 
surgical TAP block:  
Control Arm  Intervention Arm  
30 mL bupi[INVESTIGATOR_31974] 0.25%  
50 mL saline 
  
Total: [ADDRESS_1245022] 40 mL on each side  30 mL bupi[INVESTIGATOR_31974] 0.25%  
30 mL saline 20 mL (266 mg) liposomal bupi[INVESTIGATOR_889288]: [ADDRESS_1245023]-delivery.  
 Secondary outcomes will include  
• patient self-reported pain scores . 
• patient-reported incidence of side effects . 
• development of objective complications such as dysrhythmias.  
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page 14 of 42 • Percentage of postpartum people who are "opi[INVESTIGATOR_39895]" at each timepoint (12, 24, 48, 72 hours, and 
during the hospi[INVESTIGATOR_059]) with “Opi[INVESTIGATOR_39895]” defined as not receiving any opi[INVESTIGATOR_889289].  
Percentage of postpartum people who are “Opi[INVESTIGATOR_889290]” at each timepoint (12, 24, 48, 72 hours, and 
during the hospi[INVESTIGATOR_059]) with "Opi[INVESTIGATOR_889290]" defined a priori as taking ≤15 mg oral morphine equivalent 
dose at that timepoint after surgery  
Other outcomes collected will include: 
• length of stay  
• time to first rescue analgesic medication 
• total dose of opi[INVESTIGATOR_192845] 12, 24, 36, 72 hours and during the hospi[INVESTIGATOR_307] s tay 
• use of supplemental oxygen during hospi[INVESTIGATOR_5186] n 
• breastfeeding rates, both exclusive and in combination with formula use 
• amount of opi[INVESTIGATOR_889291] 
• rates of chronic pain at six weeks postpartum  
• six week Edinburgh Depression Screen scores  
• % subjects who use 0 MME in each group for each time period  
• % subjects  who used 15 MME or less  
• % subjects  who report pain score of [ADDRESS_1245024] maternal opi[INVESTIGATOR_2441].  
 
6.1.1 Primary Objective: 
• To determine whether liposomal bupi[INVESTIGATOR_889292] 48 hours after surgery.  
• Hypothesis: Our hypothesis is that liposomal bupi[INVESTIGATOR_889293] 48 hours after surgery.  
• Developmental SubAim : If liposomal bupi[INVESTIGATOR_889294], to determine the degree of the reduction in order to allow for an adequately powered randomized-controlled trial.  
 
6.1.2 Secondary Objective:  
• To determine whether liposomal bupi[INVESTIGATOR_889295]-reported pain scores and opi[INVESTIGATOR_2480]-related side effects, including 
respi[INVESTIGATOR_7798].   
• Hypothesis:  Our hypothesis is that liposomal bupi[INVESTIGATOR_889296]-reported pain scores and opi[INVESTIGATOR_27277].  
 
6.2 Endpoints 
 
6.2.1 Primary Endpoint : 
• The primary endpoint or primary objective is to reduce the total dose of opi[INVESTIGATOR_889297] [ADDRESS_1245025]-op after cesarean delivery. All opi[INVESTIGATOR_889298].  
 
6.2.2 Secondary Endpoint(s): 
• Median postoperative pain score for the first [ADDRESS_1245026]-operatively measured by [CONTACT_250115] (NRS) which rates pain on a 0-10 scale, collected routinely on the postoperatively floor by [CONTACT_889381]. UnityPoint Meriter ’s Assessment of the Postpartum Patient 
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page [ADDRESS_1245027] of Care Document #29 (UnityPoint-Health Meriter Nursing Policy Document) states that pain 
assessment documentation should be done every shift and before and after giving pain medication to 
ensure that patients are getting adequate relief. Thus, pain will be assessed approximately every 4-6 
hours. This outcome, therefore, will be recorded from the EMR.  
• Maximum and minimum pain scores every [ADDRESS_1245028].  
• Frequency of patient-reported opi[INVESTIGATOR_2480]-related side effects, such as pruritis, constipation, nausea, and mental clouding.  
• Incidence of complications of bupi[INVESTIGATOR_10319], such as local burning, nausea, dizziness, drowsiness, serious skin reactions such as blistering, confusion, blurred vision, ringing in the ears, arrhythmias, methemoglobinemia, and allergies and hypersensitivities.  
• Post-operative anti -emetic use and number of recorded epi[INVESTIGATOR_322237]. 
• Return of bowel function (measured in hours from completion of surgery to passage of flatus)  
• Length of hospi[INVESTIGATOR_4408], measured in hours from admission to time of discharge order placement 
• Time to first rescue analgesic medication, measured in minutes from arrival in the post-anesthesia care unit (PACU) until the first as needed opi[INVESTIGATOR_889299] 
• Total dose of opi[INVESTIGATOR_889300] [ADDRESS_1245029]-operatively. All opi[INVESTIGATOR_889301].  
• Total dose of opi[INVESTIGATOR_2480] s during the whole hospi[INVESTIGATOR_059]. All opi[INVESTIGATOR_889302].  
• Postoperative complications, such as urinary tract infections, thromboembolic events, pneumonia, postpartum blood transfusions, falls, myocardial infarctions.  
• Amount of opi[INVESTIGATOR_326747], measured as both the number of pi[INVESTIGATOR_889303].  
• Routine obstetric/ maternal outcomes will be collected.  
• Neonatal outcomes, including Apgar scores, NICU admission and reason, birthweight, gestational age at delivery, and other routine neonatal outcomes. 
• A secondary analysis will also be performed analyzing the effect of the liposomal bupi[INVESTIGATOR_889304].  
• We will also analyze the overall cost effectiveness of liposomal bupi[INVESTIGATOR_889305], if it is proved to reduce pain and opi[INVESTIGATOR_40533].  
 
6.2.3 Correlative objectives:  
• Breastfeeding rates, both exclusive and breastfeeding with supplementation at the time of discharge.  
• Readmission rate. 
• Whether opi[INVESTIGATOR_889306], assessed at 2 and 6 weeks postpartum.  
• Number of remaining opi[INVESTIGATOR_79534] (of those prescribed), assessed at 2 and 6 weeks postpartum.  
• Rates of ongoing pain at 2 and 6 weeks postpartum. Edinburgh Depression Screen (EDS) Scores 
assessed at 2 and 6 weeks postpartum.  
• Satisfaction scores at 2 and 6 weeks postpartum as measured by [CONTACT_889382][INVESTIGATOR_217791] (HCAHPS survey)  
 
7. Study Design 
 
7.1 General Design  
• This study will be a single-center, single blind, randomized controlled trial. The study will be conducted at UnityPoint- Health Meriter Hospi[INVESTIGATOR_889307] -Madison. Obstetric patients undergoing Cesarean delivery at UnityPoint-Health Meriter 
will be eligible.  
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page 16 of 42 • The rationale for this study being a pi[INVESTIGATOR_889308], therefore 
an effect size cannot be estimated from the literature. 
• The rationale for this study being single blind is that a control with a similar appearance to the 
liposomal bupi[INVESTIGATOR_889309]. Because the injections will not be available, the providers will be able to identify whether 
the control or intervention is being utilized.  
• The injection will occur one time and will be administered via surgical TAP block at the time of 
cesarean delivery.  
• The study groups will consist of two arms: 
o One arm will receive the intervention injection which comprises 30 mL of bupi[INVESTIGATOR_31974] 0.25%, 30 mL of saline, and 20 mL of liposomal bupi[INVESTIGATOR_10319] (266 mL) for a total of 80 mL with 40 mL injected on each side.  
o The other arm will receive the control injection which comprises 30 mL of bupi[INVESTIGATOR_31974] 0.25%, and [ADDRESS_1245030]  Selection  
 
8.1 Target Study Sample Size 
• The target sample size for a pi[INVESTIGATOR_889310] 50 with 25 subjects per arm. However, in order to account for up to a 20% dropout, we seek to randomize 60 subjects with 30 per arm.  
• We anticipate that maximum number of subjects screened to reach this sample size will be 3000. This approximates the number of women who undergo Cesarean delivery at UnityPoint-Health, Meriter in a [ADDRESS_1245031] likely scenario is that less subjects will need to be screened because many 
unplanned or urgent cesarean births would not be eligible.  
• The anticipated goal is 60 subjects randomized.  
• Subjects will be counted once they are randomized, not at the time of consent. This is because many subjects who are planning for a c esarean delivery do not ultimately have their surgery performed on the 
day that it is scheduled due to either going into labor prior to the scheduled date or having another indication for delivery prior to the scheduled date. When this occurs, randomization may or may not occur depending upon staff availability around the time of delivery.  
• Subjects will be enrolled and randomized while pregnant but when delivery via cesarean is imminent. 
The intervention will occur immediately after delivery  while the surgery is ongoing. This intervention, 
since it will occur postpartum, will not impact the fetus because at the time of intervention the pregnancy will have been completed.  
 
8.[ADDRESS_1245032] meet all of the following criteria: 
• Maternal age greater  than or equal to 18 
• Singleton or multifetal pregnancy  
• Able to receive neuraxial analgesia  
• Planned/ scheduled Cesarean delivery OR non-urgent Cesarean delivery with adequate time to consider and consent to the study  
• Able to provide consent in English  
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page 17 of 42  
8.3 Exclusion Criteria  
An individual who meets any  of the following criteria is not eligible to participate in this study and is excluded: 
• Known hypersensitivity to bupi[INVESTIGATOR_777731] (defined as a history of a reaction 
or allergy to bupi[INVESTIGATOR_10319]  (injectable, intravenous, or transdermal) reported by [CONTACT_889383])  or patient report 
• Plan by [CONTACT_889384][INVESTIGATOR_889311]. 
• Contraindication to regional  analgesia  
• Positive urine drug screen at admission to the hospi[INVESTIGATOR_307], if ordered for clinical purposes. 
• Current opi[INVESTIGATOR_889312] (reviewed by [CONTACT_976] 1-14 days prior to surgery)  
• Chronic opi[INVESTIGATOR_889240], either patient reported or documented in the medical 
record or the ePDMP (reviewed by [CONTACT_976] 1-14 days prior to surgery), defined as opi[INVESTIGATOR_889313] >3 months  
• Planned Cesarean hysterectomy (excluded due to anticipated blood loss and alternative pain control measures, possible prolonged intubation)  
• Planned vertical midline incision  
• Presence of renal dysfunction precluding the use of NSAIDs  
• Ischemic heart disease, congestive heart failure, or cardiomyopathy of pregnancy  
• Coagulopathy  
• Planned discharge from the hospi[INVESTIGATOR_889242] 48 hours postpartum  
• Unable to receive post -operative scheduled acetaminophen for any reason, such as allergy to 
acetaminophen or elevated liver function tests precluding acetaminophen use  
• Unable to receive post-operative scheduled NSAIDs for any reason, such as allergy to ketorolac or ibuprofen, or renal dysfunction precluding NSAID us e. 
• Due to an adverse event where a patient experienced local anesthetic systemic toxicity, the anesthesiology group at UPH -Meriter proposes additional exclusion criteria for this study protocol. 
These patients are still able to receive local anesthetics and bupi[INVESTIGATOR_301521], but because they are the team that would manage a toxicity reaction, they would feel more comfortable placing these TAP blocks themselves rather than having them be in this study protocol.  
• Seizure disorder: Specifically, poorly controlled seizure disorder defined as having had a seizure within the last three years despi[INVESTIGATOR_889314]-compliance.  
• Cardiac disease or arrhythmia: Defined as ischemic heart disease, peripartum cardiomyopathy, heart failure (with reduced or preserved ejection fraction, compensated or decompensated). Patients with a remote history of non-cyanotic pediatric cardiac surgery  (like a VSD closure or PDA 
ligation as a child) do not need to be excluded. History of adult cardiac surgery without ongoing problems or treatments other than chronic anticoagulation (mitral valve repair for MVP or aortic valve replacement for bicuspid aortic valve for example) would not need to be excluded. History of 
repaired congenital cyanotic heart disease should be considered for exclusion, ultimately up to the 
anesthesiologist that day. A patient with a history of arrhythmias not requiring medication or ablation would NOT need to be excluded and could be included in the study. History of ablation or active anti-arrhythmic medication should be considered for exclusion.  
• Hypoxia: Defined as requiring supplemental oxygen during the day.  
• Acidosis. This will be uncommon in our population, but if someone has active diabetic ketoacidosis will exclude.  
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page 18 of 42  
8.4 Recruitment  
• Primary obstetric providers will be made aware of this study using IRB -approved study posters, fliers, 
and brochures. 
• Providers will provide the woman with information and a consent form and have the patient sign a 
“Permission to Contact” form, performing a preoperative examination on a woman who meets criteria for 
enrollment in the study  
• The study coordinator  or study staff  will call the patient and read a prepared script about the study.  
• If the patient is interested, the study coordinator  or study staff will review the informed consent document 
during the telephone call.  
• At a following clinical appointment or on the day of surgery, the research coordinator or study staff will review again the informed consent document and the patient will sign it if they would like to participate.  
• Preliminarily eligible subjects will be invited to the Meriter Center for Perinatal Care or their assigned room in triage or the antepartum or intrapartum ward for informed consent and formal screening. 
 
8.5 Retention Strategies 
• Subjects will not be compensated for participating in this project.  
• After enrollment, there will be an in-person randomization and the surgical TAP block will be 
administered at the time of their cesarean delivery. 
• Two week postpartum follow-up will comprise questions about breastfeeding, number of opi[INVESTIGATOR_889315] (of those prescribed)  and questions about satisfaction with care.  
• Six week postpartum follow -up will comprise questions about breastfeeding, number of pi[INVESTIGATOR_889316].  
• These questions will be sent via email  message link to a secure survey for the participant to complete.  
 
8.[ADDRESS_1245033] the right to withdraw from the study at any time for any reason, without prejudice to their medical care. The investigator also has the right to withdraw patients from the study for any of the following reasons:  
• If study procedures are discontinued due to AE  
o After the intrapartum period, if the subject develops serious skin reaction, or hypersensitivity/ allergy.  
• Protocol violation 
• Study terminated 
• If the subject meets an exclusion criterion (either newly developed or not previously recognized) that precludes further study participation] 
 
Subjects who sign the informed consent form and are randomized but do not receive the study intervention will be replaced. Subjects who sign the informed consent form, are randomized and receive the study 
intervention, then subsequently withdraw, or are withdrawn or discontinued from the study, will not be 
replaced.  
 
9. Study Intervention  
 
9.[ADDRESS_1245034] administering the study injection (either the intervention injection which 
comprises 30 mL of bupi[INVESTIGATOR_31974] 0.25%, 30 mL of saline, and 20 mL of liposomal bupi[INVESTIGATOR_10319] 
(266 mL) for a total of 80 mL with 40 mL injected on each side or the control injection which comprises 30 mL of bupi[INVESTIGATOR_31974] 0.25%, and 50 mL of saline for a total of 80 mL with 40 mL 
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page 19 of 42 injected on each side) at the time of cesarean delivery. This injection will occur only once and will 
occur at the time of cesarean.   
 
9.2 Source  
The intervention drug and control  drug will be purchased by [CONTACT_889385] (PRC) pharmacy research center at the University of Wisconsin-Madison. 
Hospi[INVESTIGATOR_84059] (UWHC). The PI [INVESTIGATOR_889317].  
 
9
.3 Packaging and Labeling 
• The intervention drug will be supplied by [CONTACT_889386], Inc. (NDC [ZIP_CODE]-266-29).(30)   
• It is labeled as “Exparel (Bupi[INVESTIGATOR_40469]).  
• The instructions indicate that vials should be stored refrigerated between 2°C to 8°C (36°F to 46°F).  
• The intervention drug may be held at a controlled room temperature of 20°C to 25°C (68°F to 77°F) for up 
to [ADDRESS_1245035] (unopened) vials.   
• Do not re-refrigerate vials.  
• Do not freeze or expose liposomal bupi[INVESTIGATOR_889318] (greater than 40°C or 104°F) for an 
extended period.   
• Do not administer liposomal bupi[INVESTIGATOR_889319].  
• Do not use the vial if the stopper is bulging.   
• Handling 
• Invert vials of liposomal bupi[INVESTIGATOR_889320]-suspend the particles immediately prior to withdrawal from 
the vial.   
• Multiple inversions may be necessary to re-suspend the particles if the contents of the vial have settled.  
• Visually inspect vials for particulate matter and discoloration before use.  
• Do not filter.  
• Do not heat before use.  
• Do not autoclave.  
• Following withdrawal from the vial, store liposomal bupi[INVESTIGATOR_889321] 20°C to 25°C (68°F to 77°F) for up to 4 hours prior to administration.  
• Discard any unused portion in an appropriate manner.  
The control drug will be handled as per the usual protocol as it is already in semi -routine use for injections into 
other sites at the time of cesarean.  
 
  
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page 20 of 42 9.4 Preparation 
Both the intervention and the control injections will be prepared by [CONTACT_889387][INVESTIGATOR_31974] 
0.25% and saline as follows :  
 
Control Arm  Intervention Arm  
30 mL bupi[INVESTIGATOR_31974] 0.25%  
50 mL saline 
  
Total: [ADDRESS_1245036] 40 mL on each side  30 mL bupi[INVESTIGATOR_31974] 0.25%  
30 mL saline 
20 mL (266 mg) liposomal bupi[INVESTIGATOR_889288]: [ADDRESS_1245037] been educated on the handling of liposomal bupi[INVESTIGATOR_10319].  
 
9.5 Storage and Stability 
 
UW PRC will create study drug kits containing either the intervention or the control. These will be labeled sequentially with ascending sequential randomization numbers and will contain the medications for the 
control arm (bupi[INVESTIGATOR_889322]) or the intervention arm (bupi[INVESTIGATOR_10319], saline, and liposomal 
bupi[INVESTIGATOR_10319]). Ancillary supplies (syringes, needles) will be in a separate package. Kits stored at room temperature will need to be utilized within 30 days. Kits stored in a refrigerator will not need to be used within 30 days.  
 Kits stored in a refrigerator will be located within a locked refrigerator in a locked room.  Kits stored at room 
temperature will be within a locked cabinet in a locked room and will need to be used within 30 days.  
 After a participant is consented and randomized, we will pull the next unused kit for use with that 
participant. The participants study ID information will be recorded on a log created by [CONTACT_889388].  
 
The kit will then be brought to the operating room to use at the end of the cesarean surgery.   The physician performing the surgery will open the contents of the “kit” as described above while handling all drugs appropriately. The products will be mixed as above, and administration of the “study drug” will be documented in the operative note and the medication administration record within the electronic health 
record.  
  
Measures will be taken to ensure limited access as well as measures to prevent accident damage or destruction.  
 
If “kits” are not able to be used, we will plan to store the components separately at the temperature at 
which they are most stable and will assemble the kits as needed based upon the randomization sequence with the assembling providers blinded until the allocation envelope is opened.  
 
9.[ADDRESS_1245038]. The MOP describes the processes for the 
ordering, maintenance, and dispensing of the study drug. Investigator(s) and study team members ensure 
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page [ADDRESS_1245039] -
cesarean pain control as per hospi[INVESTIGATOR_48799]. The expected “Study Drug Schedule” is included in this documentation.  
 
The administration will occur as follows
1,2:  
 Having closed the uterus and established hemostasis at the incision, the rectus muscle is gently elevated superiorly using a retractor (figure) and the surgeon palpates its lateral border. This indirectly locates the inferior epi[INVESTIGATOR_889323]. The nerves that supply the anterior abdominal wall travel through the neurofascial plane between internal oblique and transversus abdominis mus cles. Access to this 
plane can be achieved by [CONTACT_889389] 18- [ADDRESS_1245040] surgeon move to the contralateral side of the table.  By [CONTACT_889390], the surgeon ensures no inadvertent damage to the viscera.  
Following surgical TAP block, the fascia, subcutaneous tissue, and skin are closed in the usual fashion per the usual surgical protocol.  Tip: a sponge may be inserted in the paracolic gutter to pack the bowel away if they impede access.   
  

The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page 22 of 42 Dosing location:  
 
 
 
  

The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page [ADDRESS_1245041] regional analgesia  
Prior to closing fascia  30 mL bupi[INVESTIGATOR_31974] 0.25%  
30 mL saline 
20 mL (266 mg) liposomal bupi[INVESTIGATOR_889324]: [ADDRESS_1245042] 40 mL on each side  30 mL bupi[INVESTIGATOR_31974] 0.25%  
50 mL saline 
  
    Total: [ADDRESS_1245043] 40 mL on each side  
At arrival to PACU  15 mg IV ketorolac  
+ 975 mg PO acetaminophen 15 mg IV ketorolac  
+ [ADDRESS_1245044] -op Morphine IR PO 7.5 -15 mg Q 4 hours 
PRN for moderate to severe pain*  
  
*CAN increase to 15- 30 mg Q4 hours 
PRN if pain is not controlled 
  
*CAN also use Hydromorphone IV 0.5-
1 mg Q2 hours PRN for moderate to 
severe pain for breakthrough pain or if 
not yet tolerating PO  
 
OR any other opi[INVESTIGATOR_889325] 7.5 -15 mg Q 4 hours 
PRN for moderate to severe pain*  
  
*CAN increase to 15- 30 mg Q4 hours 
PRN if pain is not controlled 
  
*CAN also use Hydromorphone IV 0.5-
1 mg Q2 hours PRN for moderate to 
severe pain for breakthrough pain or if 
not yet tolerating PO  
 
OR any other opi[INVESTIGATOR_889326] 6 hours postop  15 mg IV ketorolac (or 600 mg ibuprofen 
after 24 hours postop)  
+ 975 mg PO acetaminophen + 
Resume postoperative pain regimen  15 mg IV ketorolac (or 600 mg 
ibuprofen after 24 hours postop)  
+ 975 mg PO acetaminophen + 
Resume postoperative pain regimen  
 
9.7.2 Dose Adjustments/Modifications/Delays 
If a study participant experiences an allergic reaction to bupi[INVESTIGATOR_889327], but not limited to, pain, irritation, desire to discontinue, the study team will be notified.  
 
9.8 Randomization and Blinding 
A randomization schedule will be created by [CONTACT_889391] a block randomization with random 
block sizes of 4 or 6.   This method will ensure balance in sample size per arm throughout the entire study. Ultimately, 
there will be 30 subjects per arm for a total of 60 subjects. The study ID numbers will be sequentially assigned to 
participants  in the order that they are enrolled and consented. Randomization IDs will be sequentially assigned on the 
day of or the day before their  surgery by [CONTACT_889392]. The patient/ 
participant  will be blinded to the subject’s allocation. However, because the injections are not identical in appearance, 
the clinical team  and research coordinators  will not be blinded. Therefore, since the research coordinators are not 
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page [ADDRESS_1245045]’s allocation.  Outcome measures are objectively 
measured and participants will be blinded to allocation.  
 
9.[ADDRESS_1245046] to 
demonstrate that there is adequate monitoring of the clinical trial by [CONTACT_079] (PI) to ensure:  
• The trial is conducted according to the investigational plan, protocol and applicable laws, regulations, 
policies and guidance  
• The rights, welfare, and safety of human subjects are protected 
• Proper reporting of study data to the FDA and IRB  
• The PI [INVESTIGATOR_889328], independent safety management processes used throughout the study, including but not limited to staff training, standardized procedures, methods for data collection, study and data monitoring, and routine team meetings to review the study progress and isolate any compliance issues and/or trends.  
9.9.1 Study Team Training Members of the study team are trained on the protocol and/or study procedures applicable to their roles and responsibilities. When the protocol and/or study procedures are updated, staff will be trained on the revisions prior to implementation, as applicable.   
Per University of Wisconsin-Madison policy, all personnel engaging in human subjects research must 
complete Human Subjects Protection, and Health Insurance Portability and Accountability Act (HIPAA) training. In addition, those engaged in applicable clinical trials must also complete the Good Clinical Practice (GCP) training.]  
 
Training is documented and maintained in the study files. 
 
9.9.2 Investigator/Study Team Member Agreement  
All members of the study team are informed of their responsibilities specific to their role(s) in this study, their obligation to follow the approved clinical research protocol, the applicable regulations, guidelines and institutional policies. Documentation of this agreement is maintained in the study files.  
 
9.9.[ADDRESS_1245047] of the study  will be held on a weekly and then bi -weekly basis: 
weekly in the weeks before and immediately after study initiation and bi -weekly once the team has 
determined that weekly meeting are no longer needed by [CONTACT_256718]. In the meetings, the sponsor, sponsor -investigator, and/or the principal investigator (PI) (if not one in the same) and study 
team members discuss evaluations of study -related activities (as applicable): identification of deviations 
or noncompliance, review of adverse events, and overall study progress. Training on protocol, procedure and/or form updates may also be performed during routine meetings.  
 
9.9.5 Standardized Procedures 
 
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page 25 of 42 [IP_ADDRESS] Standard Operating Procedures (SOPs)  
Study teams are trained on and must follow the Department of Obstetrics & Gynecology (Ob/Gyn) 
Clinical Research SOPs to ensure consistent performance of procedures by [CONTACT_889393]. SOPs are periodically reviewed and updated (as necessary).  
 
[IP_ADDRESS] Manual of Procedures (MOP) The MOP is a supplemental guide to the study protocol and complements Department SOPs to 
provide additional details on the conduct of the study. It is routinely updated to ensure consistent 
performance of study activities.  
 
9.9.[ADDRESS_1245048].  Refer to the following section(s) of the protocol for additional quality assurance measures that will be 
taken.  
11. Data Collection, Handling and Record Keepi[INVESTIGATOR_007] 
12. Assessment of Safety  
14. Regulatory, Ethical, and Study Oversight Considerations  
14.[ADDRESS_1245049]-cesarean analgesia regimen as detailed above. 
Unless specifically listed in the exclusion criteria (above), other concomitant medications will be recorded on the CRF but will be permitted. Concomitant therapy might affect the outcome due to drug-drug interactions or altered metabolism.  
 
9.11 FDA IND Compliance  
The liposomal bupi[INVESTIGATOR_889329], which is its listed indication. This medication has also been used for TAP blocks at cesarean. The subjects being studied are not considered a vulnerable population, posing no additional risks regarding the 
use of the study intervention. This study does not need to be conducted under an Investigational New Drug 
(IND) application with the FDA, rather is considered IND Exempt as it is being used in the context in which it 
was approved.   
 
This study meets the IND Exemption criteria as defined by 21 CFR 312.2(b) Exemptions.  
(1) The clinical investigation of a drug product that is lawfully marketed in the [LOCATION_002] is exempt from the requirements of this part if all the following apply:  
(i) The investigation is not intended to be reported to FDA as a well -controlled study in support of a 
new indication for use nor intended to be used to support any other significant change in the labeling for the drug; The results of this study will not be reported to the FDA to support a new indication or use, or change in labeling of the drug.  
(ii) If the drug that is undergoing investigation is lawfully marketed as a prescription drug product, the 
investigation is not intended to support a significant change in the advertising for the product; The 
study intervention is lawfully marketed and is not intended to support a significant change in the advertising of the product.  
(iii) The investigation does not involve a route of administration or dosage level or use in a patient population or other factor that significantly increases the risks (or decreases the acceptability of the 
risks) associated with the use of the drug product; The study intervention will be administered using 
the dosage and route of administration as well as the patient population (in need of pain relief) that is approved.  
(iv) The investigation is conducted in compliance with the requirements for institutional review set forth 
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page 26 of 42 in part 56 and with the requirements for informed consent set forth in part 50; and the investigation 
will be conducted in compliance with the requirements for institutional review set forth in part 56 and 
with the requirements for informed consent set forth in part 50.  
(v) The investigation is conducted in compliance with the requirements of 312.7. The intervention used 
in the study will not presented as safe or effective for the purposes for which it is under investigation or otherwise promote the drug. 
 
10. Study Visits and Procedures  
 
10.1 Study Calendar  
 
Event  Activity 1  Activity 2  Activity 3  Activity 4  
Timing  Clinic , ultrasound 
unit, triage, via 
telephone, or labor 
and delivery prior 
to Cesarean delivery . 
May occur on same day as 
activity 2 or may 
occur prior.  At the time of 
Cesarean delivery  2 weeks 
postpartum  6 weeks 
postpartum  
Location  See 10.2.1   OB triage , 
antepartum unit, or 
labor and delivery 
(L&D) room  
 
L&D OR (for 
Cesarean delivery)  Pt’s home:  
Email message link to survey + (Emails  x up to 4) 
Telephone 
reminder  (If no 
prior response)  Pt’s home:  
Email message 
link to survey + (Emails  x up to 4) 
Telephone 
reminder  (If no 
prior response)  
Events  Consent  -Randomization (to 
occur day of or day 
before surgery)  
-Cesarean delivery (clinical event) 
-Liposomal 
bupi[INVESTIGATOR_889330]  
 
10.2 Screening and Enrollment  
The Screening and Enrollment activities  and procedures are described in detail below. 
 10.2.1 Prescreening 
Potentially eligible subjects will be identified and approached at different time points during pregnancy and 
at various locations. Women may be approached or consented at any of the time periods below (to allow for many possible opportunities to have the study discussed, but once they indicate they are not interested they will not be re -approached.) For each scenario, the initial approach will be done by [CONTACT_39137], residents, providers 
or other clinical staff not on the study  or study coordinators . Clinical s taff will only approach the patients about 
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page 27 of 42 participation in a research study, but not include specifics about this study. These scenarios and mechanisms 
are described below: 
 
General Recruitment and Enrollment Mechanism:  1. Providers: 
Primary obstetric providers will be made aware of this study and IRB -approved study posters, fliers, and 
brochures will be made available to interested primary obstetric providers.  a. When providers perform a preoperative examination on a woman who  meets criteria for enrollment in the 
study, they will provide the woman with information and a consent form and have the patient sign a “Permission to Contact” form.  
b. Physicians or other clinical care team member can also obtain verbal permission from the potential subject to be approached by [CONTACT_14676].  
2. Study Coordinators:  
Inpatient Only: Coordinators work with nursing staff to identify a time when patient is not sleepi[INVESTIGATOR_889331] a medical procedure to approach the patient. 
 
The study coordinator  or study staff  will then call the patient and read a prepared script about the study. If 
the patient is interested, the study coordinator or study staff will review the informed consent document during the telephone call. At a following clinical appointment or on the day of surgery, the research coordinator or study staff will review again the informed consent document and the patient will sign it if they would like to participate. Consent may also occur  via a virtual  visit.  
 
Preliminarily eligible subjects will be invited to the Meriter Center for Perinatal Care or their assigned room 
in triage or the antepartum or intrapartum ward for informed consent and formal screening.  
 
Randomization will occur the day before the planned surgery or the day of the planned surgery.  
 
Inclusion of Patients who speak Spanish 
The study will enroll subjects who speak and read either English or Spanish. 
 
All documents, including the consent and HIPPA authorization form are translated into Spanish by a 
certified medical interpreter in the UW Hospi[INVESTIGATOR_889332].   
 
An interpretation service, LanguageLine, will be used during the informed consent process, telephone 
conversations or other verbal interactions with subjects. Non -English-speaking patients who require a 
Spanish interpreter may only be consented if a language line representative is available. 
 **First Approach and Permission to Contact [CONTACT_889394].  The coordinator will call 
LanguageLine to go over the consent form or permission to contact [CONTACT_10970].  If there is no interpreter present, permission to contact [CONTACT_889395]. The patient needs to be able to understand and communicate with the coordinator. No communication will be done for research purposes until LanguageLine is available.  
 
Every effort will be made to approach Spanish speaking subjects at the same locations/circumstances as 
non-Spanish speaking patients.   
 
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page 28 of 42 Fetal anatomic examination ultrasound: Meriter Center for Perinatal Care  
Initial Approach: Patients undergoing a detailed fetal anatomic examination ultrasound (CPT code [ZIP_CODE]) at 
the Meriter Center for Perinatal Care will be provided with an information about this study. This sonogram 
typi[INVESTIGATOR_8718] 18-22 weeks gestational age, which is approximately five months prior to delivery. (CPT code [ZIP_CODE] examinations occurring at other gestational ages will also be permitted.)  However, this sonogram 
may occur at later gestational ages and information will be provided at this visit regardless of gestational age.  
 
The initial approach will be done by [CONTACT_39137], residents, providers other clinical staff or study coordinators. Clinical staff will only approach the patients about participation in a research study, but not include specifics about this 
study. Physicians or other clinical care team member can also obtain verbal permission from the potential 
subject to be approached by [CONTACT_14676].
 
 
Follow -up and Informed Consent: Research coordinators  or study staff will contact [CONTACT_889396], and they will read a prepared script to the patients to describe the study. If 
the patient is interested, an informed consent document will be mailed to the patient to review. The research 
coordinator or study staff will re-connect with the patient when the patient presents for a third trimester growth 
sonogram  or any other visit to Meriter or the day of surgery and they will review study eligibility criteria and 
whether a Cesarean delivery is planned. If a Cesarean delivery is planned, then the coordinator or study staff 
will have the patient sign an informed consent document at that time. Consent may also occur via a virtual 
visit. Then, 0-[ADDRESS_1245050] Trimester: Anesthesia preoperative consultation 
Initial Approach: At Meriter Center for Perinatal Care, some patients complete an anesthesia consultation 
during the antepartum period. This is a clinical protocol and is not related to this study. Of note, these patients would not constitute a separate cohort, but the existence of this clinic does allow providers another opportunity to identify eligible patients.  
 
The initial approach will be done by [CONTACT_39137], residents, providers other clinical staff or study coordinators. Clinical 
staff will only approach the patients about participation in a research study, but not include specifics about this study. Physicians or other clinical care team member can also obtain verbal permission from the potential 
subject to be approached by [CONTACT_14676].  
 
 
Follow -up and Informed Consent: If such patients are scheduled for a Cesarean and have an anesthesia 
appointment, the research coordinator or study staff will approach them for enrollment at their anesthesia 
preoperative appointment. This appointment typi[INVESTIGATOR_400694] 32 weeks of gestation; any gestational age will technically be eligible for approach and consent. The women, therefore, will sign consent at that time and she will be told to expect a telephone call the day before the surgery  to confirm eligibility and intent to 
participate in the surgery . Consent may also occur via a virtual visit.  
 28-38 weeks gestation ultrasound: Meriter Center for Perinatal Care Initial Approach: Patients undergoing a growth ultrasound examination (goal 28-38 weeks, but any 
gestational age acceptable) at the Meriter Center for Perinatal Care with a possible plan for scheduled cesarean will be provided with an information sheet about this study and a permission to contact [CONTACT_982]. This 
sonogram typi[INVESTIGATOR_8718] [ADDRESS_1245051] to be approached by [CONTACT_14676].   
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page 29 of 42  
Follow -up and Informed Consent: Research coordinators or study staff will contact [CONTACT_889396], and they will read a prepared script to the patients to describe the study. If the patient is interested, an informed consent document will be mailed to the patient to read and review. The research coordinator  or study staff will also attempt to directly connect with the patient around [ADDRESS_1245052] with the 
patient to confirm eligibility and desire to be in the study.  
 
Antepartum admissions with plan to remain inpatient until delivery via Cesarean Initial Approach: Occasionally women are admitted during their pregnancy and need to stay inpatient until 
delivery. Examples of such cases include women with preterm premature rupture of the fetal membranes.  
 
The initial approach will be done by [CONTACT_39137], residents, providers other clinical staff or study coordinators. Clinical 
staff will only approach the patients about participation in a research study, but not include specifics about this 
study. Physicians or other clinical care team member can also obtain verbal permission from the potential subject 
to be approached by [CONTACT_14676].   
 
Follow -up and Informed Consent: The research coordinator  or study staff will describe the study, give a copy 
of the informed consent document, and allow the patient to consider participation in this study. If the woman 
would like to participate, informed consent will be obtained, the form will be signed. Consent may also occur 
via a virtual visit.  
 
Triage, Labor & Delivery and Main Operating Room Pre- Operative Area:  
Initial Approach: The provider or research coordinator will also review the labor and delivery and main 
operating room schedule for Cesarean deliveries among women who meet inclusion criteria.  
 
The initial approach will be done by [CONTACT_39137], residents, providers other clinical staff or study coordinators. Clinical 
staff will only approach the patients about participation in a research study, but not include specifics about this 
study. Physicians or other clinical care team member can also obtain verbal permission from the potential subject to be approached by [CONTACT_14676].  
 
 
Follow -up and Informed Consent: Research coordinators or approved clinical providers will approach 
subjects, the study will be described to subjects, and informed consent will be obtained. Consent may also occur via a virtual visit. Randomization will occur that same day prior to the cesarean. Due to the busy nature 
of labor and delivery, this option may be limited to women who remain on labor and delivery for an adequate period of time to allow consideration of the study.  
 
10.2.2 Informed Consent 
The informed consent process will be conducted following all federal and institutional regulations relating to 
informed consent. Informed consent will be obtained prior to conducting any study related activities.  
At the baseline study enrollment, the participant’s eligibility will be assessed and the enrollment case report 
form will be completed. No physical examination will be performed. The estimated length of the interaction is 10-30 minutes to allow adequate time to review medical history and sign informed consent document. The informed consent process may occur in person or via telephone or video visit (remote consent) 
depending upon relevant infectious -disease related clinical and research restrictions in plac e.  
The informed consent process will be performed as follows:  
1. The research coordinator or study staff will review the informed consent form and discuss the study in detail with the potential research subject.  
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page [ADDRESS_1245053] all questions answered by [CONTACT_274788]/or PI. 
5. The informed consent document must be signed and dated by [CONTACT_2330]. 
6. The research coordinator or study staff will review the informed consent document to ensure that all 
fields that require a response are complete (i.e. checkbox marked yes or no, etc.) as applicable.  
7. The research subject will be given a copy of the signed and dated informed consent form. The original 
signed informed consent form is kept in the locked OB/GYN research office in a locked file cabinet.  
 An information sheet about the TAP block is typi[INVESTIGATOR_889333].  This might be used prior to consent when describing the study or after consent to 
clarify further questions or as part of the consent process if the surgeon is obtaining the consent.  
 Example of patient counseling about the drug and study intervention:   
Patient counseling:  
We would like to offer you a surgical transverse abdominis plane block with bupi[INVESTIGATOR_889334]. This is sometimes called a “TAP” block for short. This is a nerve block with a local anesthetic which should help reduce your pain. Historically, this block was placed by [CONTACT_889397]. However, we as surgeons are able to identify this correct location while we are doing the cesarean before we close your abdomen. This eliminates the main risk of the TAP block which is that the needle can accidentally puncture into the intestines or liver. Specific risks to all TAP blocks include bruising or hematoma formation, pain at the injection site, or inadvertent blockade of additional nerves. Risks of 
local anesthesia include cardiac risks, particularly if injected intravascularly. Other risks include 
neurotoxicity including seizures, blurred vision, ringing in the ears, and also allergic reaction. These are overall rare,  and we take precautions to avoid intravascular injection by [CONTACT_6149][INVESTIGATOR_889335]’t in a blood vessel before we inject the anesthetic.  
 
 
10.2.3 Baseline 
At the baseline study enrollment, the participant’s eligibility will be assessed, and the enrollment case 
report form will be completed. No physical examination will be performed. The estimated length of the 
interaction is [ADDRESS_1245054] Enrollment  
For this study, due to the number of potential time points to obtain consent, and the large potential for dropout between consent and randomization, enrollment will be defined as the time of randomization. This 
accounts for women who may potentially present for delivery prior to their scheduled Cesarean date or who may no longer require a Cesarean delivery (example: breech presentation at 36 weeks which verts to cephalic prior to the scheduled Cesarean).   
Procedures  
• Informed Consent will be obtained and verified at any of the interactions listed above and by [CONTACT_889398][INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page 31 of 42 • Randomization will be performed by [CONTACT_889399]  
• Delivery will occur via Cesarean delivery  
• Following delivery of the baby [CONTACT_889400], the 
surgical TAP block will be administered utilizing liposomal bupi[INVESTIGATOR_889336].  
 Postpartum  
• All pa tients receive either Intervention Injection  (liposomal bupi[INVESTIGATOR_889337]) or Control  Injection (bupi[INVESTIGATOR_889338]) at the time of cesarean in addition to 
scheduled ketorolac and scheduled acetaminophen with additional opi[INVESTIGATOR_889339] (See Table 
above) 
• Pain will be assessed via the Numeric Rating Scale (NRS), which rates pain on a 0-10 scale, by [CONTACT_291208]. Per unit protocol, this occurs every 4-6 hours.  
• Outcomes data are collected by [CONTACT_28932]  
 
10.2.5 Screen Failure and Re-enrollment  
Individuals who do not meet the criteria for participation in this trial (screen failure) due to no longer requiring a Cesarean delivery but then later have an obstetric situation change and then do require a Cesarean delivery will remain eligible. One example of this happening is a patient who has a breech baby [CONTACT_889401]. Some such patients will have 
a baby [CONTACT_889402] a Cesarean del ivery. 
Therefore, individuals who meet criteria for participation will not be removed from the study until they have 
delivered (vaginally) at which point they will no longer be eligible for participation.  
 
10.3 On-Study/Follow -up Activities  
After subjects have been enrolled, the On-Study/Follow -up activities  and the procedures are performed. 
 
Randomization: the day before or day of the Cesarean delivery  The estimated time for randomization is about [ADDRESS_1245055] their Cesarean delivery (clinical) and have the liposomal 
bupi[INVESTIGATOR_889340] .  
 
Only the physicians listed on this application (or physicians in training that these physicians are directly 
supervising) will perform the study injections. Physicians in training includes residents and fellows.   A transversus abdominis plane block is not within standard training for OB/MFMs. However, it less complicated than many other procedures that we perform, and the technique can easily be learned. The 
physicians listed in this protocol have learned this procedure and have ensured proficiency by [CONTACT_889403][INVESTIGATOR_889341] [ADDRESS_1245056] the surgical TAP block is 2.4 minutes .(14) 
The research coordinator will then collect information on the total dose of opi[INVESTIGATOR_889342]. Study participation will be recorded in the EMR under Care Coordination Plan or Problem List. 
 Post cesare an follow -up surveys  
Surveys will be emailed at 2 and 6 weeks postpartum, (each sent once if responded to, up to 4 times total sent every other day if no response) followed by a telephone call or text if there was no response to the emails. Patients who speak Spanish will only receive a phone call and not a text. The surveys can be 
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page 32 of 42 completed by [CONTACT_889404] a smart phone or computer. These study 
activities  will be completed by [CONTACT_889405], they will be 
called. Data that will be collected will include the number of opi[INVESTIGATOR_889343] (of those 
prescribed) and patient satisfaction scores. Failure to complete these surveys will not be considered a 
protocol violation. Women who respond in the affirmative that they have poor mental/emotional health, are 
feeling depressed or other questions that relate to mental health or opi[INVESTIGATOR_889344], will be referred to the 
proper mental health or addiction counselor or provider.  
 
As of this date, we do not have the means to provide non electronic survey copi[INVESTIGATOR_889345]. In a future amendment, we will determine the best method for subjects without electronic means.  
 LanguageLine has the ability to do a conference call with the subject and coordinator. We will not be able to 
use text messages for patients who do not speak English. In a future amendment, we will determine the best 
method to communicate via text to subjects who do not speak English.  
 
10.[ADDRESS_1245057] or review their consent at any time. They may also be seen postpartum for any concerns that they think may be related to the study drug. 
(example: SAEs). However, unscheduled visits are not being specifically built into this study protocol.  
 
10.[ADDRESS_1245058] the right to withdraw from the study at any time for any reason, without prejudice to their medical care. Such reasons may include (but will not be limited to):  
• Subject wishes to stop study involvement or withdraw for any reason.  
• Subject has a complication from the Cesarean delivery and wishes  to withdraw  
 The investigator also has the right to withdraw patients from the study for any of the following reasons:  
• If study procedures are discontinued due to AE  although their data would be retained for intention to treat 
analyses  
• Protocol violation 
• Study terminated 
• If subject has a delayed complication from the c esarean delivery requiring re-operation although their 
data would be retained for intention to treat analyses  
 
All data collected on subjects prior to their withdrawal or discontinuation will be retained. If a subject is withdrawn or discontinues study participation prior to their cae sarean, the subject will be discontinued and 
replaced. If the subject is withdrawn or discontinues study participation after their cae sarean, the subject will 
be followed with intent to treat and will not be replaced. The reason for subject withdrawal or discontinuation will be documented in the study records . 
 If a subject has signed informed consent but does not wish to undergo randomization, this will not count as a study discontinuation since they were not formally counted as “enrolled”.  
 
Participants  will not be informed of study results, but the results will be available to participants . These 
results would not be expected to be available until [ADDRESS_1245059]. The treatment assignments will also 
not be disclosed to the subjects at the time of the study but will be available if they would like to know after 
the six -week follow -up is complete. If subjects would like to know their treatment allocation, they may call 
research coordinators for unblinding after the 6 week follow -up is complete. 
 
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page [ADDRESS_1245060] Keepi[INVESTIGATOR_007]  
 
11.1 Data Collection  
• Standardized data collection forms (e.g., source documents, case report forms, standardized 
assessment forms, etc.) are used to ensure data collected are consistent and compliant with the protocol and IRB application.  
• Data collection is the responsibility of study team members under the supervision of the principal investigator. The principal investigator [INVESTIGATOR_19760], completeness, legibility, and timeliness of the recorded and reported data.  
• All data collection forms must be completed in a legible manner; any missing data will be explained. Data entry errors will be corrected with a single line through the incorrect entry and the correct data is entered above/near the correction. All changes w ill be initialed and dated. 
• Data collection forms are maintained in the subject files and retained as described in the Record 
Retention section.  
 
11.1.2 Data Collection Forms 
Study team members use standardized data collection forms (e.g., case report forms, source documents, etc.) to ensure data collected are consistent and compliant with the protocol and IRB application. Forms are updated per protocol amendments (as applicable). Data will be handled in accordance with applicable 
regulations, GCP guidelines, as well as institutional policies.   
 
11.1.3 Study Visit Checklists Members of the study team use study visit checklists or worksheets, developed in conjunction with the sponsor -investigator and PI (if not one in the same), to ensure that all study required procedures and 
processes are conducted before, during and after the subject has been enrolled. These checklists are completed and reviewed by [CONTACT_889406]/or perform study procedures to ensure adherence to the protocol.  
 11.1.[ADDRESS_1245061] the data are recorded. As per present, all source 
documents with patient data (i.e., “clinical metadata”) will be stored as paper records and considered the 
study source documents. All source documents will  be maintained as hard copi[INVESTIGATOR_889346] a manner accordant with the IRB protocol.  
 
11.[ADDRESS_1245062] be retained by [CONTACT_1732] a minimum of 7 years after study 
completion. Electronic data including clinical information data will be transferred to appropriate database(s). No study records shall be destroyed without prior authorization from the study PI (Antony) and/or the funding agencies, if applicable.  
 
11.3 Handling of Data to Ensure Confidentiality 
In order to ensure confidentiality of data the following procedures will be followed: 
• Label the source documents with code numbers. 
• Enter data from the source documents in a controlled-access database on the Internet or site proximal 
server.   
• Store all source documents and consent forms in a locked file cabinet(s). Only members of the study team will have access to this file cabinet.  
 
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page 34 of 42 11.4 Data collection forms 
 
11.4 Data Management Software System(s)  
Clinical data (including AEs, concomitant medications, and solicited events data) and clinical laboratory data 
will abstracted from the patient’s electronic medical record (EMR) and entered into the Research Electronic 
Data Capture (REDCap) data management software system(s) to ensure consistent data entry and data 
quality. Clinical data will be entered directly from the source.  
 REDCap is a largely self-service, secure, web-based application for building and managing data collection forms. REDCap provides data management functionality by [CONTACT_889407] 
 
11.[ADDRESS_1245063] Records 
In order to ensure confidentiality of data the following procedures will be followed: 
• Label the source documents with code numbers. 
• Enter data from the source documents in a controlled-access database on the Internet or site 
proximal server.   
• Store all source documents and consent forms in a locked file cabinet(s). Only members of the study team will have access to this file cabinet. 
 
All the staff participating in this project have undergone human subjects  protection, Good Clinical 
Practice (GCP), and HIPAA training.  Information about study subjects will be kept confidential and managed according to the requirements of the Health Insurance Portability and Accountability Act (HIPAA). All subjects will sign an informed consent document and HIPAA authorization that includes specific privacy and confidentiality rights. Study 
data will be maintained per federal, state, and institutional data policies.  
 
The Investigator (s) will ensure that the identities  of subjects are protected by [CONTACT_799876]. The log of subject identifying information that links subjects to their study-specific identification number will be maintained by [CONTACT_737]. The log and all study records will be 
maintained in locked rooms and access will be limited to essential study personnel. Electronic study 
records/files will be stored on R EDCap and on a department server  and accessed via networked 
computers that are password-protected with access provided only to authorized study personnel.  
 
Authorized representatives of the following groups may need to review this research as part of their responsibilities to protect research subjects : the study monitor, representatives of the IRB, DSMB/ DMC, 
and DCC  staff. The clinical study site will permit access to such records.  
 
Study staff may use e-mail to communicate with research subjects, if the subject has agreed to using 
email in the Informed Consent form . Prior to any email exchanges, the study staff member will review the 
Use of Email for Research Purposes Guidance. The information contained in emails will be limited to 
study activity  3 and 4 which occur at 2 and 6 weeks postpartum. All emails to subjects will be sent from 
UW/wisc.edu accounts; personal , home or Gmail email accounts will not be used.  
 
11.6 Records Retention 
It is the investigator’s responsibility to retain study essential documents for a minimum of period of [ADDRESS_1245064] 
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page [ADDRESS_1245065].  
 
12. Assessment of Safety  
 
12.1 Risk/Benefit Assessment  
 
12.1.1 Potential Benefits to the Subjects 
• There are no anticipated benefits to participating in this study.  
• One potential benefit would be reduced pain and reduced need for postoperative opi[INVESTIGATOR_37007], if 
in the intervention arm.  
• If in the control  arm, one potential benefit would be to contribute to generalizable knowledge. There 
would also potentially be benefit from the regular bupi[INVESTIGATOR_889347].   
12.1.2 Known Potential Risks & Risk Minimization 
 [IP_ADDRESS] Procedural Risks 
• There is a risk of loss of confidentiality. Measures will be taken to prevent loss of confidentiality as described in sections 11.3 Handling of Data to Ensure Confidentiality and 11.5 Data Confidentiality. 
 [IP_ADDRESS] Interventional Risks 
• There are risks of allergic reaction to regular bupi[INVESTIGATOR_889348]. There are also risks of adverse reactions as delineated above. Subjects with a known allergic reaction 
to bupi[INVESTIGATOR_889349]. Measures, such as aspi[INVESTIGATOR_889350], will also be taken to avoid adverse reactions.  
 
[IP_ADDRESS] Risk Minimization 
Described below is the rationale for the necessity of exposing subjects to risks and a summary of the ways that risks to subjects were minimized in the study design 
o Subjects with a known hypersensitivity or allergy to bupi[INVESTIGATOR_380270]  
o Regarding loss of confidentiality, paper CRF forms and ICF documents will be stored in a locked 
cabinet in the locked research coordinator’s office.  
o Online data will be stored only in secure online servers such as R EDCap and Meriter’s secure 
server.  
The risks of participation in the study outweigh the value of the information to be gained. The risks of participation in this study are overall minimal as we will not enroll patients with a known hypersensitivity or allergy to bupi[INVESTIGATOR_10319] . There is a potential benefit of pain reduction if the subject is in either arm of 
the study  compared to the standard of care which is to not administer any local anesthetic drugs via 
surgical TAP block .  
 
12.2 Unanticipated Findings 
The Office for Human Research Protections (OHRP) considers unanticipated problems involving risks to subjects or others to include, in general, any incident, experience, or outcome that meets all of the following criteria:  
• The incidence, experience, or outcome is unexpected given the research procedures described in protocol -
related documents (e.g., the study protocol, the informed consent documents, the Investigator’s Drug Brochure) and the characteristics of the subject population being studied. An event may be considered 
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page 36 of 42 unexpected if it exceeds the nature, severity, or frequency described in the study -related documents, 
Investigator’s Drug Brochure, product labeling, or package insert.  
• The incidence, experience, or outcome is related to or probably related to participation in the research study. 
Probably related means the incidence, experience, or outcome is more likely than not to be caused by [CONTACT_889408]. 
 
The occurrence of the incidence, experience, or outcome suggests that the research places subjects or 
others at a greater risk of harm (physical, psychological, economic, or social) than was previously known or recognized.   
 
12.2.1 Adventitious Findings 
No imaging studies will be obtained as part of the protocol for this study; therefore, we do not anticipate 
any adventitious findings. Other study results will not be reviewed for adventitious findings.  
 
12.[ADDRESS_1245066]’s research file. 
 
12.[ADDRESS_1245067]’s research file. 
 
12.5 Adverse Event (AE) Definition 
Adverse event (AE) means any untoward or unfavorable medical occurrence in a human subject or others 
that happens during or after participation in a research study.  
 
12.6 Serious Adverse Event (SAE) Definition 
• Results in death 
• Is life-threatening (places the subject at immediate risk of death from the event as it occurred)  
• Requires inpatient hospi[INVESTIGATOR_1081]  
o Does NOT include usual post-partum hospi[INVESTIGATOR_58170] [ADDRESS_1245068] -operative stay)  
o DOES include post-op stay >4 days  
o DOES include re-admissions after the usual postpartum hospi[INVESTIGATOR_059] 
• Results in a persistent or significant disability or incapacity  
• Results in congenital anomaly/birth defect: note, the study drug used in this study would be administered 
after delivery of the neonate  
• Any other adverse event that, based upon appropriate medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent one of the other outcomes listed in this definition.  
 12.6.5 Severity of Event  
All AEs will be assessed by [CONTACT_19811] [specify the defined grading system, e.g., the Common 
Terminology Criteria for Adverse Events (CTCAE), each event searchable using the Safety Profiler website (https://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx). For AEs not included in the protocol -defined grading 
system, the following guidelines will be used to describe severity.  
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page 37 of 42 • Mild (grade 1)  – Events require minimal or no treatment and do not interfere with the subject’s daily 
activities.  
• Moderate (grade 2) – Events result in a low level of inconvenience or concern with the therapeutic 
measures. Moderate events may cause some interference with functioning.  
• Severe (grade 3) – Events interrupt a subject’s usual daily activity and may require systemic drug therapy 
or other treatment. Severe events are usually potentially life-threatening or incapacitating. 
• Life threatening (grade 4)  - The patient was at risk of death at the time of the event.  
• Fatal (grade 5) - T he event caused death. 
 
12.6.6 Relationship to Study, Study Procedure(s) and/or Study Intervention(s) 
For all collected AEs, the clinician who examines and evaluates the subject will determine the AE’s 
causality based on temporal relationship and his/her clinical judgment. The degree of certainty about 
causality will be graded using the categories below.  
• Definitely Related – Clearly related to the study procedures /intervention and other possible 
contributing factors can be ruled out.  
• Probably Related – Likely related to the study procedures/intervention and the influence of other 
factors is unlikely.  
• Possibly Related – Possibly related to the study procedures/intervention and there are other 
factors that could be equally likely.  
• Unlikely to be related – Doubtfully related to the study procedures/intervention and there is 
another likely cause.  
• Unrelated – Clearly not related to the study procedures/intervention and/or evidence exists that the 
event is definitely related to another cause.  
 
12.6.7 Expectedness for Study, Study Procedure(s) and/or Study Intervention(s)  
The PI [INVESTIGATOR_889351](s) (as applicable) .  
 For investigational drug and device studies, an AE will be considered unexpected if the nature, severity, or frequency of the event is not consistent with the risk information previously described in the clinical protocol, device manual, investigator’s brochure, investigational drug brochure, the package insert(s), the 
IRB application, or the informed consent document. Expectedness is recorded for both study procedures 
and interventions.  
 For studies not evaluating an investigational drug or device, an AE will be considered unexpected if the nature, severity, or frequency of the event is not consistent with the risk information previously described in the clinical protocol, the IRB application, or the informed consent document. The expectedness could be based on study procedures or the characteristics of the patient population. 
 
12.7 Documenting and Reporting of AEs, SAEs & U ps 
 12.7.1 Documenting AEs, SAEs & U ps 
Adverse events will be identified by [CONTACT_889409] s with subjects or 
concerns from the nurses on the postpartum floor on a weekly basis or as needed when concerns are 
raised by [CONTACT_889410] . Study subjects wil l be instructed to contact [CONTACT_854256] (K. 
Antony) if any serious or unexpected adverse event occurs . Adverse events will be discussed at weekly 
research team meetings and will be reviewed to determine whether a change in protocol is necessary.   
 
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page 38 of 42 An abnormal laboratory result will not be assessed as an AE unless that result leads to discontinuation or 
delay in treatment, dose modification, therapeutic intervention, or is considered by [CONTACT_99347].  
 
For the purposes of this study, baseline comorbid condition s will be documented prior to the administration 
of the study intervention. Only those symptoms identified as new or worsened compared to the baseline assessment  and not related to the obstetric course will be recorded as an AE.  
 
AEs will be documented on the appropriate case report form. 
 
12.7.2 Reporting AEs, SAEs & U ps 
AE/SAEs that meet the definition of an unanticipated problem will be reported to the IRB within 14 business 
days  of learning of the event. Events that are immediately life threatening, severely debilitating to other 
current subjects or resulted in a death will be reported to the IRB Chair or IRB Director via telephone or 
email within 24 hours (1 business day) of site awareness.   All AEs will also be reported to the ICTR DMC by [CONTACT_149729]/SAE forms in ICTR REDCap and will be reported within the same timeframe as required by [CONTACT_1201]. The DMC co-chairs will review any reported 
SAE and if needed, schedule an ad hoc meeting of the full committee.   
 
12.8 Stoppi[INVESTIGATOR_889352]. Written notification, documenting the reason for study suspension or termination, will be provided by [CONTACT_87077], funding agency and the regulatory authorities. If the study is prematurely terminated or suspended, the PI [INVESTIGATOR_889353](s) for the termination or suspension.  
 
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants  
• Demonstration of efficacy that would warrant stoppi[INVESTIGATOR_007]  
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or evaluable  
• Determination of futility  
 
13. Study Analysis 
 
13.1 Statistical Hypothesis 
• Primary Efficacy Endpoint(s):  
o To determine whether liposomal bupi[INVESTIGATOR_889354].  
o Hypothesis: Our hypothesis is that liposomal bupi[INVESTIGATOR_889355] 48 hours.  
o Developmental SubAim: If liposomal bupi[INVESTIGATOR_889356], to determine the degree of the 
reduction in order to allow for an adequately powered randomized-controlled trial.  
o This will be tested by [CONTACT_889411][INVESTIGATOR_889357], calculating the total dose of opi[INVESTIGATOR_889297] [ADDRESS_1245069] size would be.  
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page [ADDRESS_1245070] 48 
hours after Cesarean delivery between the subjects randomized to the control  injection and 
subjects randomized to the intervention injection.  
 
• Secondary Efficacy Endpoint(s):  
o To determine whether liposomal bupi[INVESTIGATOR_889295] -reported pain scores and opi[INVESTIGATOR_2480]-related side effects.  
o Hypothesis: Our hypothesis is that liposomal bupi[INVESTIGATOR_889358]-reported pain scores and opi[INVESTIGATOR_27277].  
o Patient related pain scores will be compared using the Numeric rating scale (NRS) which rates pain 
on a 0-10 scale.  
o Opi[INVESTIGATOR_2480]-related side effects will be summed into a composite “Opi[INVESTIGATOR_27293]” outcome which will 
either be present or absent and Chi -Square will be used to compare the incidence of these events 
between groups. Individual components of the composite outcome will also be assessed.  
o The null hypothesis is that the patient related pain scores and the rate of opi[INVESTIGATOR_889359].  
 
13.2 Sample Size Justification  
 
This is a pi[INVESTIGATOR_799]; therefore, sample size is based on effect size estimation of liposomal bupi[INVESTIGATOR_889360]-operative opi[INVESTIGATOR_2441]. With [ADDRESS_1245071] a 95% confidence interval precision around the effect size of +/- 60% of a standard 
deviation. This will give us adequate precision in our effect size estimate to move forward with a larger 
randomized clinical trial.  In order to account for up to 20% dropout, we will seek to randomize 60 participants 
(30 per arm ).   
 
Within two years we should feasibly be able to recruit 60 women. The limitation will be that the procedure can 
only be performed by [CONTACT_889412] a surgical TAP block.  
 
13.3 Statistical Methods  
The primary outcome of total opi[INVESTIGATOR_40533] (in OME) will be compared via Student’s t-test or Mann-Whitney U test if the distribution is non-normally distributed, and additional outcomes will be assessed via Student’s t-
test, Chi -squared, or non-parametric tests, as appropriate. Statistics will be performed by [CONTACT_889413] . Analysis will be by [CONTACT_118067].  
 
No interim analysis is planned. This drug has been demonstrated to be safe, and there is a data safety 
monitoring committee who will review any significant adverse events. The data safety monitoring committee will also advise on whether early termination of the study is appropriate.  
 
Regarding missing, unused, or suspected spurious data, there will first be an attempt to validate this data via the electronic medical record. If it can be validated, the data will be used. Similarly, data points that are missing will be sought in order to have as complete a data set as possible. Otherwise, ongoing missing 
variables will be tabulated as missing. 
 
13.4 Planned Interim Analysis  
No interim analysis is planned. This drug has been demonstrated to be safe, and there is a data safety monitoring committee who will review any significant adverse events. The data safety monitoring committee will also advise on whether early termination of the study is appropriate.
 
 
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page 40 of 42 14. Regulatory, Ethical, and Study Oversight Considerations  
 
14.1 Safety Oversight  
We will also utilize the UW ICTR Data Monitoring Committee (DMC) to oversee the study. The UW ICTR 
DMC is comprised of experienced members with expertise required to oversee this study. In providing 
oversight for the conduct of this study, the ICTR DMC will meet biannually during the time period in which 
participants will have any study procedures.  At these meetings, the DMC members will review protocol -
specific reports created by [CONTACT_889414] 
(REDCap) data management tool. These standard reports will include an overview of study objectives, a review of actual and projected accrual rates, an evaluation of patient demographics for balance of 
randomization, and a summary of the number and seriousness of adverse events. Additional meetings may 
be scheduled as determined by [CONTACT_262635]. An interim analysis of study results may be performed, and source documents may be reviewed to allow the DMC to independently judge whether the 
overall integrity and conduct of the protocol remain acceptable based on data provided and reported by [CONTACT_079]. The DMC will make recommendations to the Principal Investigator [INVESTIGATOR_262597], modification, suspension, or termination.  Refer to ICTR DMC Charter for additional 
details.  
 
14.2 Protocol Deviations  
A protocol deviation is any noncompliance with the IRB approved study protocol, Good Clinical Practice (GCP), as adopted by [CONTACT_2165] (FDA), applicable federal regulations or institutional 
policies.  All deviations from the protocol must be documented and reported as required. Notably, failure of 
the subject to complete the online emailed survey in study activity [ADDRESS_1245072] with assessing secondary outcomes and are not mandatory to assess the primary outcome.  
 
14.3 Publication Plan 
If deemed appropriate, timely communication with the scientific community is one of the essential functions of 
the PI(s) and is accomplished by [CONTACT_889415]. The publication policy as it pertains to this is meant to be flexible and to 
facilitate rapid and accurate publication of results. Investigators are responsible for drafting the publications and presentations with meaningful input from study sponsors.  Internal review of manuscripts and abstracts is deemed necessary to ensure accuracy and consistent representation of concepts and data from the clinical trials.  The procedures outlined herein are guidelines and all publications of the must meet the criteria 
for authorship, disclosure, scientific integrity and other requirements of peer -reviewed scientific journals.  
Subject Study IDs are not to be used in any publications.  
  
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page 41 of 42 References 
1.  Downie DL.  Book Review: Jessica Tuchman Mathews (ed.), Preserving the Global Environment: The 
Challenge of Shared Leadership ([LOCATION_001]: W. W. Norton & Company, 1991), pp. 362. . Polit Sci. 2010;46(1):125– 6.  
2.  Hoffman SN, Han JJ, Lessons PAM, From L, Misuse PO. HHS Public Access. 2017;2(1):83– 91.  
3.  Frieden TR, Houry D. Reducing the Risks of Relief — The CDC Opi[INVESTIGATOR_2480]- Prescribing Guideline. N Engl J 
Med. 2016;374(16):1501– 4.  
4.  Bateman BT, Franklin JM, By[CONTACT_8570] K, Avorn J, Shrank WH, Brennan TA, et al. Persistent opi[INVESTIGATOR_8564]: patterns and predictors among opi[INVESTIGATOR_2480]-naïve women. Am J Obstet Gynecol. Elsevier Inc.; 2016;215(3):353.e1-353.e18.  
5.  Peahl AF, Dalton VK, Montgomery JR, Lai YL, Hu HM, Waljee JF. Rates of New Persistent Opi[INVESTIGATOR_889361]. JAMA Netw Open. 2019;2(7):1– 14.  
6.  Hedderson M, Lee D, Hunt E, Lee K, Xu F, Mustille A, et al. Enhanced Recovery After Surgery to Change Process Measures and Reduce Opi[INVESTIGATOR_27294]: A Quality Improvement Initiative. Obstet Gynecol. 2019;134(3):511– 9.  
7.  Kleiman AM, Chisholm CA, Dixon AJ, Sariosek BM, Thiele RH, Hedrick TL, et al. Evaluation of the impact 
of enhanced recovery after surgery protocol implementation on maternal outcomes following elective 
cesarean delivery. Int J Obstet Anesth. Elsevier Ltd; 2019;  
8.  Altenau B, Crisp CC, Devaiah CG, Lambers DS. Randomized controlled trial of intravenous acetaminophen for postcesarean delivery pain control. Am J Obstet Gynecol. Elsevier Inc.; 2017;10– 5.  
9.  Nedeljkovic S, Kett A, Vallejo M, Horn J, Carvalho B, Bao X, et al. Transversus Abdominis Plane Block 
With Liposomal Bupi[INVESTIGATOR_889362] a Multicenter, Randomized, Double-Blind, 
Controlled Trial. Anesth Analg. 2020;In Press( Xxx):1– 10.  
10.  Blake DW, Yew CY, Donnan GB, Williams DL. Postoperative analgesia and respi[INVESTIGATOR_889363]. Anaesth Intensive Care. 2009;37(5):720– 5.  
11.  Malik O, Kaye AD, Kaye A, Belani K, Urman RD. Emerging roles of liposomal bupi[INVESTIGATOR_889364]. J Anaesthesiol Clin Pharmacol. 2017;33(2):151– 6.  
12.  Baker BW, Villadiego LG, Lake YN, Amin Y, Timmins AE, Swaim LS, et al. Transversus abdominis plane block with liposomal bupi[INVESTIGATOR_889365]: A retrospective chart review. J Pain Res. 2018;11:3109 –16.  
13.  Patel SD, Sharawi N, Sultan P. Local anaesthetic techniques for post-caesarean delivery analgesia. Int J Obstet Anesth. Elsevier Ltd; 2019;40:62– 77.  
14.  Narasimhulu DM, Scharfman L, Minkoff H, George B, Homel P, Tyagaraj K. A randomized trial comparing surgeon-administered intraoperative transversus abdominis plane block with anesthesiologist-administered transcutaneous block. Int J Obstet Anesth. Elsevier Ltd; 2018;35:26– 32.  
15.  Owen DJ, Harrod I, Ford J, Luckas M, Gudimetla V. The surgical transversus abdominis plane block - A 
novel approach for performing an established technique. BJOG An Int J Obstet Gynaecol. 
2011;118(1):24– 7.  
16.  Kakade A, Wagh G. Evaluate the Feasibility of Surgical Transversus Abdominis Plane Block for 
Postoperative Analgesia After Cesarean Section. J Obstet Gynecol India. Springer India; 2019;69(4):330–3.  
17.  Keller DS, Madhoun N, Ponte-Moreno OI, Ibarra S, Haas EM. Transversus abdominis plane blocks: Pi[INVESTIGATOR_889366]. J Surg Res. Elsevier Inc; 2016;204(1):101– 8.  
18.  Mugabure Bujedo B. A clinical approach to neuraxial morphine for the treatment of postoperative pain. Pain Res Treat. 2012;2012.  
19.  NDA 22 -046/S -001. AccessData.FDA.Gov Bupi[INVESTIGATOR_889367]. Lake Forest, IL [ZIP_CODE] 
[LOCATION_003]; 2006.  
20.  Sharawi N, Carvalho B, Habib AS, Blake L, Mhyre JM, Sultan P. A systematic review evaluating neuraxial 
morphine and diamorphine-associated respi[INVESTIGATOR_889368]. Anesth Analg. 
2018;127(6):1385– 95.  
The Obstetric Liposomal Bupi[INVESTIGATOR_10319] (ObLiBupi) Trial   Confidential  
1.20 Version Date [09- 11-2022]   Page [ADDRESS_1245073] ( TAP 
) blocks for pain relief after caesarean section : a meta-analysis. Int J Obstet Anesth. Elsevier Ltd; 
2016;28:45– 60.  
22.  Tawfik MM, Mohamed YM, Elbadrawi RE, Abdelkhalek M, Mogahed MM, Ezz HM. Transversus abdominis 
plane block versus wound infiltration for analgesia after cesarean delivery: A randomized controlled trial. Anesth Analg. 2017;124(4):1291– 7.  
23.  Zohar E, Luban I, Zunser I, Shapi[INVESTIGATOR_2152] A, Jedeikin R, Fredman B. Patient-controlled bupi[INVESTIGATOR_889369]: The lack of efficacy of adjuvant ketamine. J Clin Anesth. 
2002;14(7):505– 11.  
24.  Behdad S, Sekhavat L, Ayatollahi V, Meshkat F, Mortazavi A. Comparison of postoperative analgesic 
effect of tramadol and bupi[INVESTIGATOR_889370]. Acta Clin Croat 2013; 2013;52:93– 7.  
25.  Niklasson B, Börjesson A, Carmnes UB, Segerdahl M, Öhman SG, Blanck A. Intraoperative injection of 
bupi[INVESTIGATOR_10319] -adrenaline close to the fascia reduces morphine requirements after cesarean section: A 
randomized controlled trial. Acta Obstet Gynecol Scand. 2012;91(12):1433– 9.  
26.  Mecklem DWJ, Humphrey MD, Hicks RW. Efficacy of Bupi[INVESTIGATOR_889371] ‐
Caesarean Section Analgesia. Aust New Zeal J Obstet Gynaecol. 1995;35(4):416– 21.  
27.  Ortega D, Viviand X, Lorec AM, Gamerre M, Martin C, Bruguerolle B. Excretion of lidocaine and 
bupi[INVESTIGATOR_889372]. Acta Anaesthesiol Scand. 
England, England; 1999 Apr;43(4):394– 7.  
28.  Prabhu M, Clapp MA, Mcquaid-hanson E, Ona S, Donnell TO, James K, et al. Liposomal Bupi[INVESTIGATOR_889373]. Obstet Gynecol. 2018;132(1):70 –
8.  
29.  Parikh P, Sunesara I, Singh Multani S, Patterson B, Lutz E, Martin JNJ. Intra-incisional liposomal bupi[INVESTIGATOR_889374]: a retrospective study. J Matern Neonatal Med. 
England; 2019 Mar;32(6):966– 70.  
30.  Pacira. INDICATIONS AND [LOCATION_003]GE EXPAREL. Initial US Approval: 1972. 2018.  
 
 